The mRNA field has spent a decade making delivery more precise. SRTD Biotech raised €31.5 million to move the targeting inside the cell, after the drug has already arrived.
Its construct enters a cell switched off. It turns on only when an antisense segment built into the RNA binds a disease-specific sequence already present in that cell, forming a double strand that triggers production of the therapeutic protein. Healthy cells lack the marker. No marker, no protein.
That is a different bet from the one most of the sector is making. Better lipid nanoparticles, better surface receptors, better tissue tropism: the delivery-first programme has absorbed most of the field's capital and most of its headlines, and that capital has produced genuine clinical progress. SRTD's seed, announced on 9 November, chose the other door.
The delivery-first camp built the roadmap
Lipid nanoparticles solved the first problem — getting RNA into a cell at all — and the industry has spent the years since refining the handoff. Targeted LNPs now redirect payloads away from the liver. Machine-learning pipelines screen ionisable lipids for organ-specific biodistribution. The current generation of companies treats the delivery vehicle as the control layer.
Kernal Biologics reported sharp gains in cell-selective translation and oncoselectivity in mouse models from a design pipeline that engineers the mRNA sequence itself, paired with T-cell-targeted LNPs. ParcelBio is developing an mRNA architecture that recruits the cell's own RNA-stabilising machinery for longer expression. Mirai Bio screened a large proprietary lipid library to shift delivery toward adipocytes and away from liver and spleen.
The logic is consistent: specificity is an engineering problem at the cell membrane, and every advance makes the vehicle smarter. It has one structural limit. A targeted particle still delivers its payload to cells that share the surface receptor, and it still activates wherever that payload lands. Delivery answers where. It does not answer whether.
| Dimension | Delivery-first | Expression-first |
|---|---|---|
| Control point | ◐ Surface receptor, tissue tropism | ✔ Intracellular RNA marker |
| Off-target logic | ◐ Payload activates wherever it lands | ✔ Payload stays dormant without marker |
| Clinical stage | ✔ Multiple programmes in or near clinic | ✗ Preclinical, IND not filed |
| Capital intensity | ◐ Platform plus manufacturing build-out | ◐ Platform plus four shared-chassis programmes |
Comparison drawn from SRTD, Kernal Biologics, ParcelBio and Mirai Bio disclosures, November 2026
The expression-first bet
SRTD's selectively expressed RNA keeps mRNA's ability to produce any protein and adds a recognition layer built from antisense chemistry. The construct carries a sensor sequence. When that sequence meets its target RNA inside a diseased cell, the resulting double strand becomes a translation trigger. The effector protein does the therapeutic work.
The effector can be swapped. In one programme it drives a tumour cell into programmed cell death. In another it reprograms cells inside liver fibrosis. In a third it dampens immune activity in autoimmune disease. SRTD lists four preclinical programmes across primary liver cancer, lung cancer, liver fibrosis and autoimmune disease, all sharing one chassis and differing only in the marker that arms them and the protein they produce.
A fusogenic lipid nanoparticle handles uptake and organ distribution: liver, lung, brain and beyond. A third platform applies bioinformatics and AI-driven RNA design to marker selection and construct optimisation. The company's claim is that this closes the loop from target discovery to a buildable molecule without redesigning the delivery system for each indication.
The scientific basis is not new. A study published in Nature Communications in January 2025 showed an seRNA construct triggering caspase-3 selectively in cancer cells; direct injection into early-stage glioblastoma tumours in mice shrank them, with no detectable side effects. That is a clean mechanism proof. It is also a local injection in an animal.
One chassis, four programmes — the platform, not a single asset, is what the seed is buying.
The proof is a 2025 mouse study; the next gate is an IND filing with no date attached.
What two pharma funds saw
The round was oversubscribed and led by Mérieux Equity Partners through its Mérieux Innovation 2 fund. NRW.BANK co-led with €7 million from its NRW.Venture EU Tech&Scale vehicle, and the Boehringer Ingelheim Venture Fund co-led alongside it. Lilly Ventures, High-Tech Gründerfonds and the Freiburg family office Anobis participated. HTGF is the only investor named in both this round and the seven-figure seed SRTD closed in November 2024 — a round this one exceeds by more than three times.
Two corporate pharmaceutical funds on a preclinical seed is the part that stands out. Corporate venture arms usually arrive after a clinical signal, when the asset is legible and the exit maths works. Here they bought into a mechanism with one mouse dataset and an IND still ahead. The bet is on the chassis: if seRNA selectivity holds in humans, the same design logic can be pointed at oncology, fibrosis and immunology, and a licensee inherits the platform rather than one molecule.
The leadership changed with the money. Matthias Alder, a 30-year biotech executive whom the company credits with more than $10 billion in transactions, took over as CEO. Heinz Koeppl, professor at TU Darmstadt and head of its Center for Synthetic Biology, became CTO. Jens Hennecke joined as chief business officer. Founders Bernd Hoffmann and Heribert Bohlen started the company in 2019 out of research at Forschungszentrum Jülich.
The gap between a mouse and an IND
Three technical questions decide whether this becomes a company or a platform paper. Distribution: whether the fusogenic LNP reaches lung and brain at therapeutic dose, not just liver. Immunity: whether repeated dosing provokes the innate response that has limited RNA medicines before. Translation: whether a marker that is clean in a mouse tumour is equally clean in human tissue, where healthy cells often express low levels of the same sequence.
None of those is answered by a €31.5 million seed. The company has given no timeline for its IND filing and no clinical trial is running. Its own 2024 ambition was to have liver cancer candidates in development within three years; the new capital is meant to buy the preclinical package that makes that possible.
✔ The case for expression-first
+ One chassis, four programmes: preclinical risk is shared across indications
+ Two pharma corporate funds validated the mechanism before any human data
Confirmation signal: an IND filing plus in vivo lung or brain distribution data.
✗ The case against
− Marker specificity in human tissue is unproven; low-level expression in healthy cells could arm the construct where it should stay silent
− Delivery-first competitors already have clinical-stage programmes and manufacturing partners
Falsification signal: off-target activation in a human-relevant model, or failure to reach lung and brain at dose.
The debate is not settled by the round size. It is settled by the first human dose. Until then, the useful distinction is this: delivery companies are optimising a vehicle, and SRTD is selling a switch. Vehicles get better incrementally. A switch either works or it does not.
Watch three things next. Whether the company publishes biodistribution data beyond the liver. Whether the pharma funds return for the Series A. And whether the IND arrives with a date attached, because that is the moment the mouse stops being the evidence.